Sichuan Biokin chases Hong Kong listing after BSM drug deal
The biopharma company has yet to market any products but one of its antibody-drug conjugates is being jointly developed in a lucrative collaboration with Bristol Myers Squibb Key Takeaways: Sichuan…
RemeGen hopes for pain relief from expanded drug uses
The innovative drug company has so far brought only two products to market, and its high sales expenses make investors worry about fallout from an anti-corruption drive Key Takeaways: RemeGen’s…
Kelun-Biotech hopes for IPO booster from new Merck partnership
The company welcomed Merck as new shareholder not long after the pair signed a lucrative licensing agreement for its cutting-edge ADC cancer treatment Key Takeaways: Despite a lack of products…
